Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Follow-Up Questions
What is the price performance of IPHYF stock?
The current price of IPHYF is $2, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Innate Pharma SA?
Innate Pharma SA belongs to Biotechnology industry and the sector is Health Care
What is Innate Pharma SA market cap?
Innate Pharma SA's current market cap is $184.3M
Is Innate Pharma SA a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Innate Pharma SA, including 1 strong buy, 5 buy, 2 hold, 0 sell, and 1 strong sell
